HPA axis and cytokines dysregulation in schizophrenia

Potential implications for the antipsychotic treatment

A. Carlo Altamura, Francesco Boin, Michael Maes

Research output: Contribution to journalArticle

Abstract

The authors discuss literature evidence on the possible dysfunctioning of HPA axis and the inflammatory response system (IRS) in schizophrenia in relation to a more comprehensive bio-pathogenetic hypothesis of the disorder and to the development of specific clinical patterns or 'core' schizophrenic symptoms, like those included in the so called negative/depressive dimension. The dysfunctions of HPA axis and IRS could be linked to some neurodevelopmental damage in relevant brain areas like hippocampus and it could involve mainly the glutamatergic pathways (e.g. NMDA receptors). Moreover, these changes could have some predictive value for response to typical antipsychotics (specifically for negative symptoms and drug resistance) in schizophrenia. Finally, the differential activity of typical versus atypical antipsychotic compounds on the basic HPA axis and IRS dysregulations in schizophrenia could account, at least partly, for the better clinical stabilization achieved in patients treated with the latter drugs compared to those receiving conventional neuroleptics.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalEuropean Neuropsychopharmacology
Volume10
Issue number1
DOIs
StatePublished - Dec 1999
Externally publishedYes

Fingerprint

Antipsychotic Agents
Schizophrenia
Cytokines
N-Methyl-D-Aspartate Receptors
Drug Resistance
Hippocampus
Therapeutics
Brain
Pharmaceutical Preparations

Keywords

  • Atypical antipsychotics
  • Cytokines
  • Drug resistance
  • HPA axis
  • Negative symptoms
  • Schizophrenia

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

HPA axis and cytokines dysregulation in schizophrenia : Potential implications for the antipsychotic treatment. / Altamura, A. Carlo; Boin, Francesco; Maes, Michael.

In: European Neuropsychopharmacology, Vol. 10, No. 1, 12.1999, p. 1-4.

Research output: Contribution to journalArticle

Altamura, A. Carlo ; Boin, Francesco ; Maes, Michael. / HPA axis and cytokines dysregulation in schizophrenia : Potential implications for the antipsychotic treatment. In: European Neuropsychopharmacology. 1999 ; Vol. 10, No. 1. pp. 1-4.
@article{764d5b1dc28b4f87bc05951dbc254744,
title = "HPA axis and cytokines dysregulation in schizophrenia: Potential implications for the antipsychotic treatment",
abstract = "The authors discuss literature evidence on the possible dysfunctioning of HPA axis and the inflammatory response system (IRS) in schizophrenia in relation to a more comprehensive bio-pathogenetic hypothesis of the disorder and to the development of specific clinical patterns or 'core' schizophrenic symptoms, like those included in the so called negative/depressive dimension. The dysfunctions of HPA axis and IRS could be linked to some neurodevelopmental damage in relevant brain areas like hippocampus and it could involve mainly the glutamatergic pathways (e.g. NMDA receptors). Moreover, these changes could have some predictive value for response to typical antipsychotics (specifically for negative symptoms and drug resistance) in schizophrenia. Finally, the differential activity of typical versus atypical antipsychotic compounds on the basic HPA axis and IRS dysregulations in schizophrenia could account, at least partly, for the better clinical stabilization achieved in patients treated with the latter drugs compared to those receiving conventional neuroleptics.",
keywords = "Atypical antipsychotics, Cytokines, Drug resistance, HPA axis, Negative symptoms, Schizophrenia",
author = "Altamura, {A. Carlo} and Francesco Boin and Michael Maes",
year = "1999",
month = "12",
doi = "10.1016/S0924-977X(99)00017-6",
language = "English (US)",
volume = "10",
pages = "1--4",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - HPA axis and cytokines dysregulation in schizophrenia

T2 - Potential implications for the antipsychotic treatment

AU - Altamura, A. Carlo

AU - Boin, Francesco

AU - Maes, Michael

PY - 1999/12

Y1 - 1999/12

N2 - The authors discuss literature evidence on the possible dysfunctioning of HPA axis and the inflammatory response system (IRS) in schizophrenia in relation to a more comprehensive bio-pathogenetic hypothesis of the disorder and to the development of specific clinical patterns or 'core' schizophrenic symptoms, like those included in the so called negative/depressive dimension. The dysfunctions of HPA axis and IRS could be linked to some neurodevelopmental damage in relevant brain areas like hippocampus and it could involve mainly the glutamatergic pathways (e.g. NMDA receptors). Moreover, these changes could have some predictive value for response to typical antipsychotics (specifically for negative symptoms and drug resistance) in schizophrenia. Finally, the differential activity of typical versus atypical antipsychotic compounds on the basic HPA axis and IRS dysregulations in schizophrenia could account, at least partly, for the better clinical stabilization achieved in patients treated with the latter drugs compared to those receiving conventional neuroleptics.

AB - The authors discuss literature evidence on the possible dysfunctioning of HPA axis and the inflammatory response system (IRS) in schizophrenia in relation to a more comprehensive bio-pathogenetic hypothesis of the disorder and to the development of specific clinical patterns or 'core' schizophrenic symptoms, like those included in the so called negative/depressive dimension. The dysfunctions of HPA axis and IRS could be linked to some neurodevelopmental damage in relevant brain areas like hippocampus and it could involve mainly the glutamatergic pathways (e.g. NMDA receptors). Moreover, these changes could have some predictive value for response to typical antipsychotics (specifically for negative symptoms and drug resistance) in schizophrenia. Finally, the differential activity of typical versus atypical antipsychotic compounds on the basic HPA axis and IRS dysregulations in schizophrenia could account, at least partly, for the better clinical stabilization achieved in patients treated with the latter drugs compared to those receiving conventional neuroleptics.

KW - Atypical antipsychotics

KW - Cytokines

KW - Drug resistance

KW - HPA axis

KW - Negative symptoms

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0032759229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032759229&partnerID=8YFLogxK

U2 - 10.1016/S0924-977X(99)00017-6

DO - 10.1016/S0924-977X(99)00017-6

M3 - Article

VL - 10

SP - 1

EP - 4

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 1

ER -